Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SUM159 cells treated with H3B-8800 or DMSO, J2 enrichment for dsRNA

ABSTRACT: SUM159 cells treated with H3B-8800 or DMSO, J2 enrichment for dsRNA

PROVIDER: PRJNA685161 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

SUM159 cells treated with H3B-8800 or DMSO, J2 enrichment for dsRNA

Project description:The objective is to identify splicing and expression changes that occur after spliceosome inhibition in triple-negative breast cancer, specifically after the RNA has been enriched for double-stranded structure using the J2 antibody.

2020-12-17 | GSE163188 | GEO

SUM159 cells treated with H3B-8800 or DMSO, Cytoplasmic fraction RNA-seq

Project description:SUM159 cells treated with H3B-8800 or DMSO, Cytoplasmic fraction RNA-seq

| PRJNA685408 | ENA

Chronic Lymphocytic Leukemia MEC1 SF3B1 K700E and Wild Type Cell Lines' RNA-seq after Treatment with H3B-8800 Splicing Modulator.

Project description:To study the impact of SF3B1 mutations on alternative splicing and the effect of H3B-8800 splicing modulator in wild type and SF3B1-mutant chronic lymphocytic leukemia cells, we established SF3B1 K700E MEC1 CLL isogenic cell line and carried out RNA deep sequencing in SF3B1 wild type and K700E MEC1 cell lines upon H3B-8800 treatment.

2023-08-08 | GSE190087 | GEO

H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [K562]

Project description:Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factors SF3B1, U2AF1, and SRSF2 that confer an alteration of function. Although cells bearing these mutations are preferentially dependent on wild-type (WT) spliceosome function, clinical means to therapeutically target the spliceosome do not currently exist. Here, we describe an orally available modulator of the SF3b complex, H3B-8800, which potently and selectively kills spliceosome-mutant epithelial and hematologic malignancies. The effects of H3B-8800 are entirely selective for the Sf3b complex, as evidenced by the identification of drug-resistant cells bearing mutations in Sf3b components. Although H3B-8800 modulates RNA splicing mediated by WT or cancer-associated SF3B1 mutants, its preferential effects on spliceosome-mutant cells is due to preferred retention of short, GC-rich introns, which are enriched in genes encoding a substantial number of spliceosome components. These data demonstrate the therapeutic potential of splicing modulation in spliceosome-mutant cancers.

2017-12-20 | GSE94528 | GEO

H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers [Nalm-6]

2017-12-20 | GSE94999 | GEO

T11, AT3, PyMT-M, 2208L GEMM tumors treated with H3B-8800

Project description:T11, AT3, PyMT-M, 2208L GEMM tumors treated with H3B-8800

| PRJNA685157 | ENA

H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers

Project description:H3B-8800, a novel oral splicing modulator, induces lethality in spliceosome mutant cancers

| PRJNA375127 | ENA

Gene expression regulation in MCF7 cells by H3B-6545, H3B-9709, Fulvestrant and Tamoxifen

Project description:In the cellular setting, both H3B-6545 and H3B-9709 were confirmed to be non-degraders and had nearly identical impact on global gene expression changes

2022-03-15 | GSE178303 | GEO

SUM159 cells treated with H3B-8800 or DMSO, Cytoplasmic fraction RNA-seq

Project description:The objective is to identify splicing changes that occur after spliceosome inhibition in triple-negative breast cancer, specifically in cytoplasmic RNA.

2020-12-17 | GSE163232 | GEO